Canada's Psilocybin Patients: Compassionate Access & Real-World Outcomes
An overview of how Canadian patients have accessed psilocybin through Health Canada's Special Access Program — covering eligibility, the clinical framework, patient-reported outcomes, and what real-world use reveals about psilocybin's therapeutic promise beyond controlled trial settings.
Source Research Papers
Citations in APA 7 format. All studies were sourced from peer-reviewed journals via Google Scholar. Unfamiliar terms? See the plain-language glossary →
de la Salle, S., Kettner, H., Thibault Lévesque, J., Garel, N., Dames, S., Patchett-Marble, R., Rej, S., Gloeckler, S., Erritzoe, D., Carhart-Harris, R., & Greenway, K. T. (2024). Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. Scientific Reports, 14, 15353. https://doi.org/10.1038/s41598-024-66817-0
26 Canadians who received psilocybin therapy through a special-access program reported real, lasting improvements in their mental health. It wasn't a controlled trial, but it's a valuable look at how the treatment works outside the lab.
Shop Related Spores
Laboratory-grade Psilocybe cubensis spore syringes for microscopy research.